Why the study?
Does sacubitril/valsartan reduce NT-proBNP compared to enalapril, and does this reduction correlate with lower rates of cardiovascular death or heart failure hospitalization in patients with heart failure?
Does sacubitril/valsartan reduce NT-proBNP compared to enalapril, and does this reduction correlate with lower rates of cardiovascular death or heart failure hospitalization in patients with heart failure?
Sacubitril/valsartan is superior to enalapril in reducing NT-proBNP, a reduction that is prognostically linked to improved clinical outcomes in heart failure.
Sacubitril/valsartan more reliably achieves prognostic NT-proBNP levels; confirms biomarker response predicts lower CV death or HF hospitalization.
Patients who attained a significant reduction in NT-proBNP had a lower subsequent rate of cardiovascular death or HF hospitalization independent of the treatment group. Treatment with sacubitril/valsartan was nearly twice as likely as enalapril to reduce NT-proBNP to values ≤1,000 pg/ml. (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial) [PARADIGM-HF]; NCT01035255.).
No takes yet. Share an insight, caveat, or question.
Zile et al. (2016) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: